Physician profile
Laura Th Wang
NPI 1730136144
$1,942.31
in general payments reported to CMS, 2019-2025
27 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $262 · 2020: $145 · 2021: $406 · 2022: $383 · 2023: $498 · 2024: $105 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $640 · Education: $107.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $639.55 |
| Education | $106.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $709.47 | 2019-2023 | Orilissa, Lo Loestrin Fe, Liletta |
| Astellas Pharma US INC | $388.18 | 2023-2025 | Veozah |
| Pfizer INC. | $102.92 | 2020-2023 | |
| Exeltis, USA INC. | $82.57 | 2021-2025 | Slynd |
| Daiichi Sankyo INC. | $71.17 | 2019-2025 | Injectafer |
| Exact Sciences Corporation | $61.22 | 2023-2024 | Cologuard Collection Kit |
| Duchesnay USA Incorporated | $48.12 | 2019 | |
| Therapeuticsmd, INC. | $46.51 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $45.58 | 2019-2020 | |
| Myovant Sciences INC. | $38.54 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $38.18 | 2021-2022 | |
| Mylan Pharmaceuticals INC. | $31.89 | 2021-2022 | |
| Scynexis, INC. | $30.62 | 2022 | |
| Coopersurgical, INC. | $26.06 | 2019-2022 | |
| Agile Therapeutics, INC. | $23.08 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $20.83 | 2024 | |
| Mycovia Pharmaceuticals, INC. | $20.82 | 2022 | |
| Mayne Pharma Commercial LLC | $20.69 | 2021 | |
| Baxter Healthcare | $20.11 | 2025 | Perclot |
| Sumitomo Pharma America, INC. | $19.53 | 2023 | Myfembree |
| Evofem Biosciences, INC. | $18.03 | 2021 | |
| Sage Therapeutics, LLC | $17.64 | 2024 | |
| Pharmacosmos Therapeutics INC. | $13.55 | 2024 | Monoferric |
| Millicent US INC | $13.14 | 2019 | |
| Covidien LP | $12.21 | 2019 | |
| Allergan, INC. | $12.05 | 2019 | |
| Aspira Women'S Health INC | $9.60 | 2023 | Ova1 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.